Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

[Pharmacokinetics and tissue distribution of irinotecan hydrochloride nanoparticles].

Yang FY, Zhang WP, Chen HL, Fu Y, Wang XY, Wei SJ, Yang XY, Zhang YX, Dang HW.

Yao Xue Xue Bao. 2013 Jun;48(6):940-5. Chinese.

PMID:
23984532
2.
3.

Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice.

Schluep T, Cheng J, Khin KT, Davis ME.

Cancer Chemother Pharmacol. 2006 May;57(5):654-62. Epub 2005 Aug 26.

PMID:
16133526
4.

Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.

Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T.

Cancer Chemother Pharmacol. 1998;42(4):280-6.

PMID:
9744772
5.

Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats.

Machida Y, Onishi H, Kurita A, Hata H, Morikawa A, Machida Y.

J Control Release. 2000 May 15;66(2-3):159-75.

PMID:
10742577
6.

Food-drug interaction of (-)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38.

Lin LC, Wang MN, Tsai TH.

Chem Biol Interact. 2008 Aug 11;174(3):177-82. doi: 10.1016/j.cbi.2008.05.033. Epub 2008 Jun 5.

PMID:
18579105
7.

Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.

Yang XX, Hu ZP, Chan SY, Duan W, Ho PC, Boelsterli UA, Ng KY, Chan E, Bian JS, Chen YZ, Huang M, Zhou SF.

Curr Drug Metab. 2006 May;7(4):431-55.

PMID:
16724931
8.

Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion.

Kurita A, Kado S, Kaneda N, Onoue M, Hashimoto S, Yokokura T.

Cancer Chemother Pharmacol. 2003 Nov;52(5):349-60. Epub 2003 Aug 6.

PMID:
12904895
9.

Preparation and antitumor characteristics of PLA/(PEG-PPG-PEG) nanoparticles loaded with camptothecin.

Kunii R, Onishi H, Machida Y.

Eur J Pharm Biopharm. 2007 Aug;67(1):9-17. Epub 2007 Jan 28.

PMID:
17337172
10.

Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients.

Slatter JG, Schaaf LJ, Sams JP, Feenstra KL, Johnson MG, Bombardt PA, Cathcart KS, Verburg MT, Pearson LK, Compton LD, Miller LL, Baker DS, Pesheck CV, Lord RS 3rd.

Drug Metab Dispos. 2000 Apr;28(4):423-33.

11.

Pharmacokinetics of hydroxycamptothecin nanosuspensions in rats.

Wang L, Hua HY, Liu WJ, Zhao YX, Zhang ZZ.

Pharmazie. 2011 Jul;66(7):547-8.

PMID:
21812333
12.

Determination of irinotecan and its metabolite SN-38 in rabbit plasma and tumors using a validated method of tandem mass spectrometry coupled with liquid chromatography.

Park DJ, Won JH, Cho AR, Yun HJ, Heo JH, Hwhang TH, Lee DH, Kim WM.

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jul 1;962:147-52. doi: 10.1016/j.jchromb.2014.05.042. Epub 2014 May 27.

PMID:
24927278
13.

Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats.

Itoh T, Itagaki S, Sasaki K, Hirano T, Takemoto I, Iseki K.

J Pharm Pharmacol. 2004 Jun;56(6):809-12.

PMID:
15231047
14.

Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.

Bissery MC, Vrignaud P, Lavelle F, Chabot GG.

Anticancer Drugs. 1996 Jun;7(4):437-60.

PMID:
8826613
16.

Influence of route of administration on [3H]-camptothecin distribution and tumor uptake in CASE-bearing nude mice: whole-body autoradiographic studies.

Ahmed AE, Jacob S, Giovanella BC, Kozielski AJ, Stehlin JS Jr, Liehr JG.

Cancer Chemother Pharmacol. 1996;39(1-2):122-30.

PMID:
8995509
17.

Effect of injection routes on pharmacokinetics and lactone/carboxylate equilibrium of 9-Nitrocamptothecin in rats.

Chen J, Ping Q, Guo J, Liu M, Cai B.

Int J Pharm. 2007 Aug 1;340(1-2):29-33. Epub 2007 Mar 12.

PMID:
17446016
18.

Irinotecan-encapsulated double-reverse thermosensitive nanocarrier system for rectal administration.

Din FU, Choi JY, Kim DW, Mustapha O, Kim DS, Thapa RK, Ku SK, Youn YS, Oh KT, Yong CS, Kim JO, Choi HG.

Drug Deliv. 2017 Nov;24(1):502-510. doi: 10.1080/10717544.2016.1272651.

PMID:
28181835
19.

Liquid chromatographic-tandem mass spectrometric assay for the simultaneous quantification of Camptosar and its metabolite SN-38 in mouse plasma and tissues.

Bardin S, Guo W, Johnson JL, Khan S, Ahmad A, Duggan JX, Ayoub J, Ahmad I.

J Chromatogr A. 2005 May 6;1073(1-2):249-55.

PMID:
15909526
20.

Salivary drug monitoring of irinotecan and its active metabolite in cancer patients.

Takahashi T, Fujiwara Y, Sumiyoshi H, Isobe T, Yamaoka N, Yamakido M.

Cancer Chemother Pharmacol. 1997;40(5):449-52.

PMID:
9272124

Supplemental Content

Support Center